Jefferies Financial Group Inc. Invests $1.74 Million in InflaRx N.V. $IFRX

Jefferies Financial Group Inc. purchased a new position in shares of InflaRx N.V. (NASDAQ:IFRX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 775,349 shares of the company’s stock, valued at approximately $1,737,000. Jefferies Financial Group Inc. owned about 0.53% of InflaRx as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Sanctuary Advisors LLC purchased a new stake in InflaRx in the second quarter worth $25,000. Cubist Systematic Strategies LLC boosted its stake in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the period. HRT Financial LP bought a new position in shares of InflaRx in the fourth quarter worth about $47,000. Concurrent Investment Advisors LLC grew its holdings in shares of InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares during the last quarter. Finally, Insigneo Advisory Services LLC bought a new stake in InflaRx during the 4th quarter valued at about $61,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Down 1.8%

Shares of IFRX stock opened at $2.23 on Friday. The firm has a market cap of $328.64 million, a price-to-earnings ratio of -3.84 and a beta of 2.48. The company’s 50 day moving average is $1.99 and its 200 day moving average is $1.65. InflaRx N.V. has a 52-week low of $0.80 and a 52-week high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Analysts anticipate that InflaRx N.V. will post -0.31 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on IFRX. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Wednesday, June 24th. Zacks Research cut InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. HC Wainwright raised their price objective on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $7.00 to $9.00 in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, InflaRx has an average rating of “Moderate Buy” and an average price target of $7.33.

InflaRx Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.